Dr. Harsha Rajasimha work over the last 17 years has focused on data-driven, value-based, precision medicine R&D and commercial programs for cancer and other diseases. He serves on the commercial relevance advisory board of BioHealth Innovation, a non-profit organization attracting investments to Maryland. Earlier, he led the global strategy and business development for Strand Life Sciences, a CAP/CLIA precision medicine diagnostics company and Bioinformatics powerhouse.
Dr. Rajasimha has led the development of some of the largest genomics projects including PathogenPortal, Pathosystems resource integration center, Cancer Biomedical Informatics Grid (caBIG), LIMS implementation at the FDA Office of Regulatory Affairs, architected Genome Explorer® a web-based platform for next-generation sequencing (NGS) data analysis for Genome International Corporation and Cyberinfrastructure development for National Eye Institute’s genomics program. His contributions to the NGS program were recognized by NEI director’s innovation award in 2012. More recently, in collaboration with rare genomics institute, he received the Sanofi Genzyme patient advocacy leadership award 2016 and a NTT DATA Healthcare and Life Sciences Silver award for outstanding achievement and impact on business unit’s fiscal year initiatives 2017.
Dr. Rajasimha has authored over 15 peer-reviewed articles, book chapters, inventor on patents and is often invited speaker at international conferences and executive consultant/advisor to a number of biotech startups. He has contributed to global data standards initiatives such as GA4GH, BioPAX, DELSAGlobal, and the personalized medicine coalition. He earned baccalaureate degree in computer engineering from Bangalore University, Masters in Computer Science and Doctorate in genetics, bioinformatics and computational biology from Virginia Tech.